Purpose: This paper aims to report collective information on safety and efficacy of empagliflozin drug repurposing in individuals with glycogen storage disease type Ib (GSD Ib). Methods: This is an international retrospective questionnaire study on the safety and efficacy of empagliflozin use for management of neutropenia/neutrophil dysfunction in patients with GSD Ib, conducted among the respective health care providers from 24 countries across the globe. Results: Clinical data from 112 individuals with GSD Ib were evaluated, representing a total of 94 treatment years. The median age at start of empagliflozin treatment was 10.5 years (range = 0-38 years). Empagliflozin showed positive effects on all neutrophil dysfunction–related symptoms, including oral and urogenital mucosal lesions, recurrent infections, skin abscesses, inflammatory bowel disease, and anemia. Before initiating empagliflozin, most patients with GSD Ib were on G-CSF (94/112; 84%). At the time of the survey, 49 of 89 (55%) patients previously treated with G-CSF had completely stopped G-CSF, and another 15 (17%) were able to reduce the dose. The most common adverse event during empagliflozin treatment was hypoglycemia, occurring in 18% of individuals. Conclusion: Empagliflozin has a favorable effect on neutropenia/neutrophil dysfunction–related symptoms and safety profile in individuals with GSD Ib.

Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire / Grunert, S. C.; Derks, T. G. J.; Adrian, K.; Al-Thihli, K.; Ballhausen, D.; Bidiuk, J.; Bordugo, A.; Boyer, M.; Bratkovic, D.; Brunner-Krainz, M.; Burlina, A.; Chakrapani, A.; Corpeleijn, W.; Cozens, A.; Dawson, C.; Dhamko, H.; Milosevic, M. D.; Eiroa, H.; Finezilber, Y.; Moura de Souza, C. F.; Garcia-Jimenez, M. C.; Gasperini, S.; Haas, D.; Haberle, J.; Halligan, R.; Fung, L. H.; Horbe-Blindt, A.; Horka, L. M.; Huemer, M.; Ucar, S. K.; Kecman, B.; Kilavuz, S.; Krivan, G.; Lindner, M.; Lusebrink, N.; Makrilkakis, K.; Mei-Kwun Kwok, A.; Maier, E. M.; Maiorana, A.; Mccandless, S. E.; Mitchell, J. J.; Mizumoto, H.; Mundy, H.; Ochoa, C.; Pierce, K.; Fraile, P. Q.; Regier, D.; Rossi, A.; Santer, R.; Schuman, H. C.; Sobieraj, P.; Spenger, J.; Spiegel, R.; Stepien, K. M.; Tal, G.; Tansek, M. Z.; Torkar, A. D.; Tchan, M.; Thyagu, S.; Schrier Vergano, S. A.; Vucko, E.; Weinhold, N.; Zsidegh, P.; Wortmann, S. B.. - In: GENETICS IN MEDICINE. - ISSN 1098-3600. - (2022). [10.1016/j.gim.2022.04.001]

Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire

Rossi A.;
2022

Abstract

Purpose: This paper aims to report collective information on safety and efficacy of empagliflozin drug repurposing in individuals with glycogen storage disease type Ib (GSD Ib). Methods: This is an international retrospective questionnaire study on the safety and efficacy of empagliflozin use for management of neutropenia/neutrophil dysfunction in patients with GSD Ib, conducted among the respective health care providers from 24 countries across the globe. Results: Clinical data from 112 individuals with GSD Ib were evaluated, representing a total of 94 treatment years. The median age at start of empagliflozin treatment was 10.5 years (range = 0-38 years). Empagliflozin showed positive effects on all neutrophil dysfunction–related symptoms, including oral and urogenital mucosal lesions, recurrent infections, skin abscesses, inflammatory bowel disease, and anemia. Before initiating empagliflozin, most patients with GSD Ib were on G-CSF (94/112; 84%). At the time of the survey, 49 of 89 (55%) patients previously treated with G-CSF had completely stopped G-CSF, and another 15 (17%) were able to reduce the dose. The most common adverse event during empagliflozin treatment was hypoglycemia, occurring in 18% of individuals. Conclusion: Empagliflozin has a favorable effect on neutropenia/neutrophil dysfunction–related symptoms and safety profile in individuals with GSD Ib.
2022
Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire / Grunert, S. C.; Derks, T. G. J.; Adrian, K.; Al-Thihli, K.; Ballhausen, D.; Bidiuk, J.; Bordugo, A.; Boyer, M.; Bratkovic, D.; Brunner-Krainz, M.; Burlina, A.; Chakrapani, A.; Corpeleijn, W.; Cozens, A.; Dawson, C.; Dhamko, H.; Milosevic, M. D.; Eiroa, H.; Finezilber, Y.; Moura de Souza, C. F.; Garcia-Jimenez, M. C.; Gasperini, S.; Haas, D.; Haberle, J.; Halligan, R.; Fung, L. H.; Horbe-Blindt, A.; Horka, L. M.; Huemer, M.; Ucar, S. K.; Kecman, B.; Kilavuz, S.; Krivan, G.; Lindner, M.; Lusebrink, N.; Makrilkakis, K.; Mei-Kwun Kwok, A.; Maier, E. M.; Maiorana, A.; Mccandless, S. E.; Mitchell, J. J.; Mizumoto, H.; Mundy, H.; Ochoa, C.; Pierce, K.; Fraile, P. Q.; Regier, D.; Rossi, A.; Santer, R.; Schuman, H. C.; Sobieraj, P.; Spenger, J.; Spiegel, R.; Stepien, K. M.; Tal, G.; Tansek, M. Z.; Torkar, A. D.; Tchan, M.; Thyagu, S.; Schrier Vergano, S. A.; Vucko, E.; Weinhold, N.; Zsidegh, P.; Wortmann, S. B.. - In: GENETICS IN MEDICINE. - ISSN 1098-3600. - (2022). [10.1016/j.gim.2022.04.001]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/885932
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 27
social impact